515 related articles for article (PubMed ID: 23810462)
1. Therapeutics for HIV-1 reactivation from latency.
Sgarbanti M; Battistini A
Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
[TBL] [Abstract][Full Text] [Related]
2. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
3. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
4. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
Dhamija N; Rawat P; Mitra D
Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
[TBL] [Abstract][Full Text] [Related]
6. Underlying mechanisms of HIV-1 latency.
Romani B; Allahbakhshi E
Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
[TBL] [Abstract][Full Text] [Related]
7. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
8. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
9. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
10. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
[TBL] [Abstract][Full Text] [Related]
12. Progress and challenges in the use of latent HIV-1 reactivating agents.
Shang HT; Ding JW; Yu SY; Wu T; Zhang QL; Liang FJ
Acta Pharmacol Sin; 2015 Aug; 36(8):908-16. PubMed ID: 26027656
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
[TBL] [Abstract][Full Text] [Related]
14. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
Søgaard OS; Graversen ME; Leth S; Olesen R; Brinkmann CR; Nissen SK; Kjaer AS; Schleimann MH; Denton PW; Hey-Cunningham WJ; Koelsch KK; Pantaleo G; Krogsgaard K; Sommerfelt M; Fromentin R; Chomont N; Rasmussen TA; Østergaard L; Tolstrup M
PLoS Pathog; 2015 Sep; 11(9):e1005142. PubMed ID: 26379282
[TBL] [Abstract][Full Text] [Related]
15. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
Shan L; Siliciano RF
Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
[TBL] [Abstract][Full Text] [Related]
16. Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?
Cromer D; Pinkevych M; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021399
[TBL] [Abstract][Full Text] [Related]
17. A broad drug arsenal to attack a strenuous latent HIV reservoir.
Stoszko M; Ne E; Abner E; Mahmoudi T
Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C
J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485
[TBL] [Abstract][Full Text] [Related]
19. Latency reversal and viral clearance to cure HIV-1.
Margolis DM; Garcia JV; Hazuda DJ; Haynes BF
Science; 2016 Jul; 353(6297):aaf6517. PubMed ID: 27463679
[TBL] [Abstract][Full Text] [Related]
20. Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus.
Hori T; Barnor J; Nguyen Huu T; Morinaga O; Hamano A; Ndzinu J; Frimpong A; Minta-Asare K; Amoa-Bosompem M; Brandful J; Odoom J; Bonney J; Tuffour I; Owusu BA; Ofosuhene M; Atchoglo P; Sakyiamah M; Adegle R; Appiah-Opong R; Ampofo W; Koram K; Nyarko A; Okine L; Edoh D; Appiah A; Uto T; Yoshinaka Y; Uota S; Shoyama Y; Yamaoka S
Biochem Biophys Res Commun; 2015 Apr; 459(2):288-293. PubMed ID: 25727021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
